---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000027"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-05-11T20:11:11+00:00"
generated_at: "2026-05-11T22:16:45.792366+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AbCellera reports Q1 net loss $43.2M; positive Phase 1 data for ABCL635 supports monthly dosing

## Summary
- Net loss of $43.2M ($0.14 loss per share) vs $45.6M loss in Q1 2025; revenue $8.3M up from $4.2M.
- Total available liquidity ~$655M ($531M cash + $124M non-dilutive government funding).
- ABCL635 Phase 1: favorable tolerability, no liver toxicity; half-life ~24 days supports monthly subcutaneous dosing.
- ABCL635 showed sustained dose-dependent suppression of testosterone, a validated NK3R biomarker.
- Partner-led programs with downstreams: 40 (down from 44); 14 molecules in clinic unchanged.

## SEC filing metadata
- accession: 0001703057-26-000027
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-05-11T20:11:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/0001703057-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/abcl-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000027
- JSON: https://secwatch.observer/filing/0001703057-26-000027.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.